Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.56 |
| ▸ | GRM5 | P41594 | 12/20 | 0.49 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897966 | 1.00 | USP30 (0.56) | USP30GRM5SCD5HCRTR1HCRTR2 | |
| SCHEMBL2899277 | 0.89 | USP30 (0.57) | USP30GRM5SCD5HCRTR1HCRTR2 | |
| SCHEMBL2899271 | 0.89 | USP30 (0.57) | USP30GRM5SCD5HCRTR1HCRTR2 | |
| SCHEMBL17063898 | 0.89 | HCRTR1 (0.57) | USP30SCD5HCRTR1HCRTR2 | |
| SCHEMBL17063895 | 0.89 | HCRTR1 (0.57) | USP30SCD5HCRTR1HCRTR2 | |
| SCHEMBL13876923 | 0.89 | HCRTR1 (0.57) | USP30SCD5HCRTR1HCRTR2 | |
| SCHEMBL5485310 | 0.88 | USP30 (0.68) | USP30GRM5HCRTR1HCRTR2 | |
| SCHEMBL14387336 | 0.88 | USP30 (0.56) | USP30SCD5HCRTR1HCRTR2 | |
| SCHEMBL8226169 | 0.88 | USP30 (0.56) | USP30SCD5HCRTR1HCRTR2 | |
| SCHEMBL2897851 | 0.86 | SCD5 (0.59) | USP30SCD5HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027120-A2 | MGLUR5 MODULATORS I | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | USP30 3125/4885GRM5 1/4885SCD5 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.